StockCIK 1933414
Mineralys Therapeutics, Inc. (MLYS): Insider Trades and Fund Holdings
In the past 12 months, Mineralys Therapeutics, Inc. insiders reported 0 open-market purchases worth $0 and 5 sales worth $5.40M; 4 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$5.40MSold by insiders, 12 months
1Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 2, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 2 | Jon CongletonCEO | ▼ SELL10b5-1 | $1.91M |
| Sep 24 | Brian Taylor SlingsbyDirector | ▼ SELL | $3.01M |
| Sep 22 | Eric WarrenChief Commercial Officer | ▼ SELL10b5-1 | $209K |
| Sep 17 | Daphne KarydasDirector | ▼ SELL10b5-1 | $86K |
| Aug 25 | Eric WarrenChief Commercial Officer | ▼ SELL10b5-1 | $193K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Jon Congleton | CEO | 0 | $0 | 1 | $1.91M |
| Brian Taylor Slingsby | Director | 0 | $0 | 1 | $3.01M |
| Eric Warren | Chief Commercial Officer | 0 | $0 | 2 | $402K |
| Daphne Karydas | Director | 0 | $0 | 1 | $86K |
Tracked funds that report MLYS
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 378,300 | $10.2M | ▼ −1.2% |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →